
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Edison Oncology Holding Corp. (‘Edison Oncology’), a company established to develop

